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ABSTRACT: The human endometrium is a complex tissue comprised of different
cell types, including epithelial, stromal, inflammatory, perivascular, and blood
vessel cells. The hormonal receptivity and distribution of these cell populations
change during the menstrual cycle. Cyclical endometrial growth is dependent
on its ability to regenerate a vascular capillary network, which grows in parallel
with the proliferation and differentiation of the endometrial lining. Natural
hormonal effects on the endometrium and endocrine manipulation of this tis-
sue, in response to the use of exogenous steroid therapies, can affect endometri-
al capillary proliferation and function, leading to clinical abnormalities of
uterine bleeding. We propose that the regulation of endometrial angiogenesis is
mediated indirectly via complex interactions among cell types. Our laboratory
has focused on a prototypical member of the angiogenic proteins, vascular en-
dothelial growth factor (VEGF)-A. In this paper we present data demonstrating
that VEGF-A expression in normal endometrial epithelial and stromal cells and
in Ishikawa adenocarcinoma cells is increased by an ovarian steroid, estradiol.
Infiltrating immune cells, particularly polymorphonuclear granulocytes, also
are sources of VEGF-A. In inflammatory conditions involving the endometrium
(e.g., endometriosis), a proinflammatory cytokine, IL-1, can mediate neoan-
giogenesis by inducing VEGF-A gene transcription. Thus, endometrial vascu-
larization is effected by both endocrine and paracrine pathways. 
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 INTRODUCTION
Endometrial angiogenesis, as with neovascularization in other sites, requires the
sprouting of new capillaries from preexisting vessels. This complex process involves
the proteolytic degradation of extracellular matrix, the proliferation and migration
of endothelial cells, and ultimately the formation of patent capillary tubules supply-
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ing the growing endometrium. Few normal adult tissues are as dynamic as the human
endometrium, whose thickness grows up to 10-fold each month after menstrual
desquamation. The precise regulation of its vascularization, critical to endometrial
perfusion, embryonic implantation, and survival of the species, is understood poorly.
Many growth factors and cytokines have been shown to exert chemotactic, mitoge-
nic, or inhibitory activity on endothelial cells, smooth muscle cells, and pericytes
and to participate in angiogenic processes either directly or indirectly. As angiogen-
esis occurs when the balance of local factors promoting vascular growth exceeds the
action of vascular inhibitors, several different regulatory mechanisms are possible.
In this paper we focus on the upregulation of a prototypical angiogenic factor, vas-
cular endothelial growth factor (VEGF)-A, as a key mediator of neovascularization.
Several pleiotropic growth factors (e.g., basic FGF, PDGF, TGF-β, and interleu-
kin [IL]-6) have been shown to exert angiogenic activities.1 By contrast, the 43-kD,
dimeric, heparin-binding glycoprotein VEGF-A is specifically mitogenic for endo-
thelial cells,2 and VEGF receptors are restricted primarily to endothelial and tropho-
blast cells. Five molecular species of VEGF-A have been identified to date
(VEGF121, VEGF145, VEGF165, VEGF189, and VEGF201), each named for the
length of its amino acid sequence. The different mature proteins arise via alternative
splicing of a single primary mRNA transcript. The dominant VEGF-A mRNA tran-




Cyclical vascular changes within the primate endometrium were first documented
in the classical experiments of Markee.5 Heterotopic transplants of rhesus endometri-
um into the anterior chamber of the eye could be observed directly in this model. The
functionalis layer of endometrium is supplied by an end-arteriole, referred to as the
spiral arteriole. Each arteriole is responsible for the perfusion of ~4–7 mm2 of en-
dometrium. These vessels, unlike the radial and basal arteries that feed them, are
highly sensitive to ovarian steroids. The endometrial vascular architecture changes
throughout the menstrual cycle, paralleling growth of the supporting epithelium and
stroma. From days 0–25, there is a gradual increase in branching and coiling of spiral
arterioles, corresponding to an increase in the length and coiling of endometrial
glands. A decade later, in their landmark article, Noyes and colleagues6 reported ef-
fects of enhanced vascular permeability and perivascular edema during the human
endometrial cycle, providing further evidence that steroids from the ovary orches-
trate vascular responses in normal endometrium. Beginning in the late proliferative
phase, under the influence of ovarian estradiol production, a complex subepithelial
capillary plexus develops in the cycling endometrium.7 The capillary endothelial
cells also acquire mitogenic activity, evidenced by [3H]thymidine incorporation in
tissue explants obtained at this cycle phase.8 More recent morphometric evaluations
of endometrial vessel formation indicate significant variation in endothelial cell pro-
liferation within different regions of the uterus. Samples from hysterectomy speci-
mens show that the endothelial cell proliferation index is significantly elevated in
functionalis compared with basalis layer vessels.9
In the last decade it has become apparent that some steroid hormone actions on
uterine tissues are not direct but are effected by paracrine mediators such as cyto-
kines and growth factors.10 Cytokines are key mediators of intercellular communi-
cation within the immune system and can exert proliferative, cytostatic,
chemoattractant, or differentiative effects on the surrounding endometrium. The cur-
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rent studies sought to evaluate the potential mechanisms of VEGF-A gene regulation
vis-à-vis the neovascularization of normal endometrium and endometriotic implants.
The in vitro models used in the following experiments were designed to test hormone
and cytokine responses of cells from the endometrial functionalis layer. Primary cell
cultures were derived from Pipelle biopsy material, which yields predominantly su-
perficial endometrial glands and stroma. Transfected Ishikawa cell models were de-
signed to approximate the ovarian steroid receptor phenotype of functionalis
epithelium, which differs from that of the underlying basalis zones.11
MATERIALS AND METHODS
Subjects and Specimens
Normally menstruating women undergoing laparoscopy for various indications
were recruited. Women who had taken oral contraceptives, hormonal supplements,
or gonadotropin-releasing hormone (GnRH) analogs over the previous 3 months
were excluded. Control subjects were identified at laparoscopy for tubal sterilization
or for assessment of pelvic pain in whom no visible evidence of pelvic pathology
was found. Subjects with endometriosis were identified when laparoscopy revealed
the presence of classical or atypical endometriotic lesions. Clinical staging of en-
dometriosis followed the revised modification of the American Fertility Society
scoring system, as described.12 Endometrial biopsies and resection of endometriotic
ovarian cysts were performed with the patient under anesthesia. All subjects provid-
ed written informed consent under a protocol approved by the Committee on Human
Research at the University of California, San Francisco. 
Immunohistochemistry
Endometrial tissue specimens were fixed for 24 hours in Histochoice MB
(Amresco, Solon, OH), paraffin embedded, and cut in serial sections of 8 µm. Sec-
tions were stained with a rabbit polyclonal anti-human VEGF-A antiserum (Santa
Cruz Antibodies, Santa Cruz, CA) at a concentration of 10 µg/ml using the
Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA). Negative controls
for immunostaining were performed using normal rabbit serum at the identical pro-
tein concentration (10 µg/ml), as described previously.13 Immunostaining for poly-
morphonuclear granulocytes was performed using mouse monoclonal antibodies
against human neutrophil elastase (2 µg/ml, Zymed, So. San Francisco, CA). Nega-
tive controls for immunostaining were performed using an irrelevant, isotype-specif-
ic mouse monoclonal antibody (anti-synaptophysin) at the identical protein
concentration (2 µg/ml), as described previously.14,15 The chromagen signal was en-
hanced with NiSO4 using the Liquid Diaminobenzidine-Black Substrate kit (Zymed,
South San Francisco, CA).
Establishment of Human Endometrial Cell Cultures
The techniques for isolation and culture of human endometrial and endometriotic
stromal cells in vitro were described in detail elsewhere.12 Briefly, follicular phase
endometrial biopsies from control women were used to prepare cultures of normal
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endometrial cells, and endometriotic ovarian cysts were used as the source of en-
dometriotic cells. The specimens were minced, digested with collagenase, and seri-
ally filtered through narrow gauge sieves with apertures of 38–105 µm to trap the
glandular epithelium. Stromal cells were plated and allowed to adhere to plastic cell-
culture dishes for 30 minutes, at which time contaminating epithelial and blood cells
and tissue debris were rinsed free. Epithelial cells were backwashed from the cell
sieves and plated onto Matrigel-coated culture wells. Stromal cells were subcultured
twice to eliminate contamination by immunocytes. All experiments were performed
with cells at passage zero (epithelium) or two (stroma), within 14 days of initial iso-
lation. Under these conditions the primary cells retain estrogen receptor (ER) mRNA
and protein.12,16 Purity of the epithelial and stromal cell populations was confirmed
by positive immunostaining for cytokeratin and vimentin, respectively, using specif-
ic mouse anti-human monoclonal antibodies.12
Polarized Endometrial Epithelial Cell Cultures
In some experiments, human proliferative phase endometrial epithelial cells were
grown under polarizing conditions.17 Primary endometrial epithelial cells were pre-
pared from biopsies, as described above, and plated onto polyethylene terephthalate
Transwell culture inserts with a pore size of 0.4 µm (Becton Dickinson, Lincoln
Park, NJ). The cells were cultured in MEM-α reconstituted with 10% fetal calf se-
rum (FCS), nucleosides, essential amino acids, 100 U/ml penicillin G, and 100 µg/
ml streptomycin.
Steroid and Cytokine Treatment
Prior studies documented the presence of ER-α and ER-β mRNA and functional
ER proteins in endometrial stromal cells cultured in vitro.16 Confluent cultures of
endometrial stromal cells and Ishikawa adenocarcinoma cells were incubated over-
night in low-serum medium (phenol red–free MEM-α supplemented with 2.5% dex-
tran-charcoal stripped FBS, nucleosides, antibiotics, and nonessential amino acids)
and exposed to 10 or 100 nM E2 or vehicle (ethanol) control for an additional 24
hours. The latter concentration was used in Ishikawa cells transfected with the hu-
man ER-α cDNA (HEO), as this construct carries a point mutation that renders the
Kd ∼70% higher than that of the wild-type ER.18
Similar experiments were performed in primary endometrial stromal cells using
10 ng/ml IL-1β (R&D Systems, Minneapolis, MN) or 100 ng/ml tumor necrosis fac-
tor (TNF)-α and interferon (IFN)-γ (Sigma Chemical Co., St. Louis, MO). All the
cytokines were recombinant human proteins, to which the endometrial stromal cells
were exposed for up to 24 hours. These doses previously were shown to optimally
induce IL-619 and RANTES (regulated on activation, normal T-cell expressed and
secreted)20 expression in primary endometrial stromal cell cultures.
Quantification of VEGF-A Protein and mRNA
At the end of each experiment, conditioned media were aspirated and centrifuged
to pellet floating cells, and the supernatants were assayed for secreted VEGF165 us-
ing a sensitive sandwich ELISA developed at Genentech, Inc. (South San Francisco,
CA).13 The cells were lysed in TriZOL reagent (Gibco-BRL, Gaithersburg, MD),
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and total RNA was isolated and subjected to formaldehyde gel electrophoresis.
Northern blotting with random-primed [α-32P]dCTP-labeled VEGF and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) cDNA probes was performed as de-
scribed.15 In some experiments with Ishikawa cells, semiquantitative reverse
transcription-polymerase chain reaction (RT-PCR) assays were used to estimate the
concentration of VEGF-A mRNA relative to GAPDH mRNA.15 Actinomycin D, an
inhibitor of DNA-dependent RNA synthesis, was used at a concentration of 5 µg/ml
to prove that mRNA accumulation was the result of transcriptional, rather than post-
transcriptional, control.21
Quantification of VEGF-A Gene Promoter Activity
VEGF-A promoter-luciferase reporter constructs were designed as described22
and contained 2.3 kb of the human VEGF-A gene promoter upstream of firefly lu-
ciferase cDNA in the pGL2 reporter vector (Promega, Minneapolis, MN). These
plasmids were transiently transfected into primary endometrial epithelial and strom-
al cells and into Ishikawa adenocarcinoma cells by calcium phosphate precipitation,
lipofection, and electroporation, respectively, as described.22
Data Analysis and Statistics
The data are expressed as the mean ± SEM. Paired Student’s t tests were used.
Statistical significance was accepted at p <0.05 for two-tailed analyses. 
RESULTS
Immunohistochemical staining of endometrial biopsy specimens from normal
women revealed both epithelial and stromal expression of VEGF-A, as we and oth-
ers reported previously.13,23 Typically, the epithelial staining pattern was more
prominent, with secretory vacuoles showing concentrated VEGF-A protein
(FIG. 1A). Endometrial stromal cells were labeled more diffusely for VEGF-A, with
an appearance suggestive of extracellular matrix localization of the protein
(FIG. 1A). Isolated round cells within the endometrial stroma (arrow) and endome-
trial vessels (arrowhead) also were stained brightly by the anti-VEGF-A antiserum
(FIG. 1A). These cells were identified as polymorphonuclear granulocytes by their
intense reaction with human neutrophil elastase antibodies in adjacent sections
(FIG. 1B). Double immunoenzymatic labeling techniques, described elsewhere,
proved that the same cells coexpressed human neutrophil elastase and VEGF-A.15
Monolayers of primary endometrial epithelial cells were established in bicameral
chambers.20 The development of high electrical resistance (868 ± 53 Ω/cm2, mean ±
SD) and the establishment of a gradient of [125I]ovalbumin added to the upper cham-
ber of the epithelial cell–lined Transwell inserts verified the integrity of the polarized
endometrial epithelial monolayer. In these cells we noted a fivefold higher ratio of
apical to basal VEGF secretion (p <0.05). By contrast, directional secretion of a sol-
uble isoform of fibronectin was not statistically different in the same cells (FIG. 2).
Other in vitro models were established to investigate the regulation of VEGF-A
mRNA and protein in these cells. Endometrial stromal cells cultured in the presence
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of 10 nM E2, to mimic the endocrine milieu of the late proliferative phase, showed
an increase in VEGF-A mRNA accumulation (3.1-fold increase; TABLE 1). Ishikawa
cells expressed basal levels of VEGF-A mRNA, but these did not change after expo-
sure to up to 100 nM E2. However, following transfection with physiological con-
centrations of functional human ER-α (HEO, ∼20,000 receptors/cell), treatment
with 100 nM E2 caused a 2.0-fold stimulation in steady-state levels of VEGF-A
transcripts (TABLE 115).
Exposure of normal endometrial stromal cells to IL-1β had no effect on steady-
state VEGF transcript concentrations (TABLE 2) and failed to increase VEGF secre-
tion by these cells. Likewise, treatment of the stromal cells with TNF-α and IFN-γ
for 24 hours failed to induce VEGF protein secretion.21 By contrast, endometriotic
stromal cells, derived from ovarian endometrioma tissue, manifested a three- to four-
fold upregulation of VEGF-A mRNA accumulation and protein secretion after ex-
posure to IL-1β. The former effect was blocked by preincubation with actinomycin
D, an inhibitor of mRNA synthesis, indicating a transcriptional mechanism of
action.
Direct transcriptional regulation of the VEGF-A gene was examined by transfect-
ing VEGF-A promoter-luciferase vectors into primary endometrial epithelial and
stromal cells by calcium phosphate precipitation and lipofection, respectively. Re-
porter plasmids containing 2.3 kb of the human VEGF-A gene promoter were tested
in primary endometrial epithelial and stromal cells and in the Ishikawa adenocarci-
TABLE 1. Estradiol effects on VEGF mRNA accumulation in endometrial cells
Cell type Hormone treatment
VEGF mRNA
(arbitrary units)
Endometrial stromal cells Control (0.1% ethanol) 1.0
10 nM E2 3.1 ± 1.8a
Ishikawa cells Control 1.0
100 nM E2 1.1 ± 0.5
Ishikawa cells transfected with ER-α Control 1.0
100 nM E2 2.0 ± 0.2a
ap <0.05 (paired Student’s t test).
TABLE 2. Cytokine effects on VEGF mRNA accumulation in endometrial cells





Endometrial stromal cells Control 1.0 64 ± 34
0.6 nM IL-1β 0.8 ± 0.1 45 ± 7
Endometriosis stromal cells Control 1.0 162 ± 93
0.6 nM IL-1β 2.6 ± 0.2a
ap <0.05 (paired Student’s t test).
671 ± 470a
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noma cell line.22 Treatment with 10 nM E2 induced a three- to fourfold activation of
the promoter in both endometrial epithelial and stromal cells (FIG. 3, histograms 1
and 2). Transfection of the same construct into Ishikawa adenocarcinoma cells failed
to respond to E2 at concentrations up to 100 nM (FIG. 3, histogram 3). However, co-
transfection of vectors expressing functional human ER-α, restored E2 responsive-
ness of the VEGF-A gene promoter (FIG. 3, histogram 4).
DISCUSSION
Although changes in endometrial capillary proliferation and permeability are
modulated during the ovarian cycle and with exogenous steroids, endothelial cells
per se may not be direct targets of classical ER (α) or progesterone receptor-
mediated effects. Receptors for these steroids are present in human uterine artery
smooth muscle, but have not been identified convincingly in endothelium in
situ.24,25 Using the highly sensitive reverse transcriptase-PCR approach, we26 and
others27 were unable to detect either ER-α or ER-β mRNAs in human umbilical vein
endothelium. However, functional evidence of ER-mediated gene activation and gel
mobility shift assays have been reported by some investigators using these cells.28
Nuclear progesterone receptors have been reported in murine endothelial cells29 and
human endometrial endothelium.30 In general, however, it is believed that ovarian
steroid effects on angiogenesis are mediated indirectly via the paracrine actions of
prostaglandins or polypeptide growth factors derived from nearby endometrial epi-
thelial or stromal cells.
Findings in the current study confirm previous results from ourselves13 and
others31 that VEGF-A gene expression is upregulated in isolated human endometrial
cells by E2. This endocrine milieu models that observed in the late proliferative
FIGURE 2. Vectorial secretion of VEGF-A from polarized endometrial epithelial cells.
VEGF-A was secreted preferentially into the apical compartment of Transwell chambers
(open histogram), whereas fibronectin secretion (closed histogram) was similarly distribut-
ed into the apical and basal chambers.
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phase of the menstrual cycle. Estrogens upregulate VEGF mRNA and protein pro-
duction in uterine tissues and cells. If similar results are confirmed in endometriotic
tissues, these studies support the obligatory role of estrogen on endometriosis
implants32 and the observation that downregulating doses of GnRH analogues,
which diminish circulating E2 levels, also decrease the size and vascularity of en-
dometriosis lesions.33 However, while microvascular growth and VEGF-A expres-
sion are temporally correlated within the endometrium, a clear correlation between
VEGF intensity and markers of endothelial cell proliferation is disputed.34 It is like-
ly that coexpression of other angiogenic factors and substrates (e.g., basic FGF,
VEGF receptors, or angiopoietins) also are required for full vascularization of this
tissue.
The apical localization in situ and secretion in vitro of VEGF-A remain a curious
observation. We have proposed that this angiogenic factor also may affect blastocyst
function. Hemochorial placentation, such as that observed in human pregnancy, is
associated with the development of an endothelial-like phenotype of trophoblastic
cells.35 Invasive first trimester human cytotrophoblasts and cultured choriocarcino-
ma cells both express the flt-1 and KDR receptors for VEGF-A.36 Hence, endome-
trial luminal VEGF-A may provide a trophic signal to the implanting human
blastocyst.
Using the same in vitro cell model, we failed to observe effects of IL-1β (IL-1β),
TNF-α, and IFN-γ  on VEGF expression in normal endometrial stromal cells, despite
the known actions of all three cytokines on other bioactive proteins (e.g., IL-619 and
RANTES20). However, we did observe that cytokines can increase VEGF-A mRNA
and protein expression in stromal cells derived from endometriotic lesions. Thus,
proinflammatory cytokines are mediators of neovascularization in endometriotic
implants.
FIGURE 3. Estradiol induction of VEGF-A promoter-luciferase activity in primary en-
dometrial epithelial cells, primary endometrial stromal cells, and nontransfected and ER-α-
transfected (HEO) Ishikawa adenocarcinoma cells.
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It is unlikely that ovarian steroids are direct mediators of endometrial angiogen-
esis. Most investigators have failed to identify detectable levels of classical estrogen
(α) or progesterone (A and B) receptors in endometrial vascular endothelial
cells.25,37 However, in some recent reports, immunohistochemistry and RT-PCR
demonstrated estrogen and progesterone receptor expression in human endometrial
endothelial cells.29,30 In the latter study, progesterone-receptor complexes were re-
ported to inhibit mitotic activity of endothelial cells. Further studies will be needed
to clarify whether some endothelial cells have direct ovarian steroid responses.
The cloned human VEGF gene promoter consists of 2.4 kb of DNA upstream
from the transcription start site and a long 5′ untranslated region.38 Initiation of
VEGF mRNA synthesis is modulated by sequence-specific consensus sites that bind
transcriptional control factors. Analyses of the primary sequence of the VEGF pro-
moter reveal several common response elements, including: AP-1, AP-2, and hy-
poxia-induced enhancer sequences in this gene.39–43
Although no consensus palindromic estrogen response element (ERE) sequence
exists in the 2.4-kb VEGF promoter, E2 treatment increases VEGF mRNA as early
as 1 hour after hormone administration, suggesting a direct regulation of VEGF gene
transcription.13 VEGF gene expression also has been shown to be regulated rapidly
by E2 in the rat uterus.
44 We recently identified a functional variant ERE about
1.5 kb 5′ to the transcription initiation site of the human gene promoter,22 and Hyder
and colleagues44 reported an estrogen-dependent element in the 3′ untranslated re-
gion of the VEGF-A gene.
Estrogen-receptor complexes classically bind as dimers to consensus, 13-bp pal-
indromic EREs.45 Although few natural genes contain perfect palindromic EREs,
ER complexes also can activate components of the AP-1 complex (e.g., c-fos and c-
jun)46 or bind imperfect EREs if a GATA-6 sequence is present nearby.39 As de-
scribed herein, IL-1β can upregulate VEGF in endometriotic stromal cells and has
been demonstrated in other cell types.47 It has been postulated that this cytokine ef-
fect is mediated via NFκB motifs located in the VEGF promoter.48 This hypothesis
is under examination currently in our laboratory.
In summary, we propose that endocrine and paracrine modulation of endometrial
angiogenesis is mediated via transcriptional upregulation of VEGF-A gene expres-
sion in endometrial stromal and epithelial cells. VEGF-A is an angiogenic factor of
hierarchical importance, particularly in the uterus, where it responds to multiple
stimuli. Steroids, cytokines, and chemokines, by virtue of their recruitment of
VEGF-A–producing inflammatory cells, allow fine-tuning of endometrial vascular-
ization. Interruption of single or multiple pathways within this complex network
should provide therapeutic opportunities for the amelioration of vascular abnormal-
ities associated with endometrial disorders such as endometriosis and dysfunctional
uterine bleeding.
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